AC Immune’s ACI-24 Shows Promising Early Data in Alzheimer’s Trial
Event summary
- AC Immune reported interim 12-month data from the Phase 1b/2 ABATE trial of ACI-24 in prodromal Alzheimer’s disease, showing safety and antibody responses at all dose levels.
- The ongoing AD4 cohort is testing an additional adjuvant to enhance immunogenicity.
- Takeda’s agreement includes up to $2.1 billion in potential milestones and double-digit royalties upon commercialization.
The big picture
AC Immune’s positive interim data for ACI-24 reinforces its position in the competitive Alzheimer’s disease therapeutic space. The strategic partnership with Takeda, including substantial milestone payments and royalties, underscores the potential scale of this collaboration. Success here could validate AC Immune’s SupraAntigen® platform and attract further investment in neurodegenerative disease treatments.
What we're watching
- Clinical Efficacy
- Whether the enhanced adjuvant in Cohort AD4 will improve plaque removal and overall efficacy.
- Regulatory Pathway
- The pace at which AC Immune can advance ACI-24 through further clinical trials and potential approval.
- Partnership Dynamics
- How Takeda’s involvement will shape the future development and commercialization of ACI-24.
Related topics